JAMA paper delves into Merck staph vaccine flunk

A paper in JAMA has revealed details of the Merck ($MRK) Staphylococcus aureus vaccine trial that was stopped early in 2011 amid safety concerns. The vaccine was no more effective than a placebo, and was associated with a rise in multiorgan failure. Article

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.